Published in J Pharmacol Exp Ther on June 28, 2012
Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility. J Med Chem (2016) 1.10
Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems. Pharmacol Rev (2016) 1.02
Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists. Br J Pharmacol (2014) 0.97
The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability. ACS Chem Neurosci (2012) 0.94
Designing bifunctional NOP receptor-mu opioid receptor ligands from NOP receptor-selective scaffolds. Part I. Bioorg Med Chem Lett (2013) 0.87
Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain. J Pharmacol Exp Ther (2013) 0.86
Supraspinal actions of nociceptin/orphanin FQ, morphine and substance P in regulating pain and itch in non-human primates. Br J Pharmacol (2015) 0.86
Discovery of a Potent Analgesic NOP and Opioid Receptor Agonist: Cebranopadol. ACS Med Chem Lett (2014) 0.85
Central N/OFQ-NOP Receptor System in Pain Modulation. Adv Pharmacol (2015) 0.82
Discovery of Spiro[cyclohexane-dihydropyrano[3,4-b]indole]-amines as Potent NOP and Opioid Receptor Agonists. ACS Med Chem Lett (2014) 0.81
A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates. Proc Natl Acad Sci U S A (2016) 0.80
Quantitative Signaling and Structure-Activity Analyses Demonstrate Functional Selectivity at the Nociceptin/Orphanin FQ Opioid Receptor. Mol Pharmacol (2015) 0.80
Bifunctional Peptide-Based Opioid Agonist-Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic Pain. J Med Chem (2016) 0.79
Effects of the NOP agonist SCH221510 on producing and attenuating reinforcing effects as measured by drug self-administration in rats. Eur J Pharmacol (2014) 0.77
Characterisation of the Novel Mixed Mu-NOP Peptide Ligand Dermorphin-N/OFQ (DeNo). PLoS One (2016) 0.77
C7β-methyl analogues of the orvinols: the discovery of kappa opioid antagonists with nociceptin/orphanin FQ peptide (NOP) receptor partial agonism and low, or zero, efficacy at mu opioid receptors. J Med Chem (2015) 0.75
Characterization of the Discriminative Stimulus Effects of a NOP Receptor Agonist Ro 64-6198 in Rhesus Monkeys. J Pharmacol Exp Ther (2016) 0.75
Pharmacological characterization of cebranopadol a novel analgesic acting as mixed nociceptin/orphanin FQ and opioid receptor agonist. Pharmacol Res Perspect (2016) 0.75
Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in mice. Eur J Pharmacol (2015) 0.75
Drug synergism: its detection and applications. J Pharmacol Exp Ther (2001) 4.11
Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry (1978) 3.33
Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br J Pharmacol (1977) 2.61
Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol (1995) 2.34
Dose-response pharmacology of intrathecal morphine in human volunteers. Anesthesiology (1993) 2.01
Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Ther (2001) 2.00
Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol (2000) 1.97
Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther (1995) 1.73
Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine. Eur J Pain (2008) 1.67
Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci (2003) 1.59
A synthetic agonist at the orphanin FQ/nociceptin receptor ORL1: anxiolytic profile in the rat. Proc Natl Acad Sci U S A (2000) 1.57
Current knowledge of buprenorphine and its unique pharmacological profile. Pain Pract (2010) 1.53
Buprenorphine: considerations for pain management. J Pain Symptom Manage (2005) 1.40
The role of central mu opioid receptors in opioid-induced itch in primates. J Pharmacol Exp Ther (2004) 1.33
Opioids and the treatment of chronic pain: controversies, current status, and future directions. Exp Clin Psychopharmacol (2008) 1.32
Characterization of opiates, neuroleptics, and synthetic analogs at ORL1 and opioid receptors. Eur J Pharmacol (2001) 1.30
Activities of mixed NOP and mu-opioid receptor ligands. Br J Pharmacol (2007) 1.30
Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers. J Pharmacol Exp Ther (1997) 1.26
Dose-response relationship of intrathecal morphine for postcesarean analgesia. Anesthesiology (1999) 1.26
In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br J Pharmacol (1981) 1.21
Opioid interactions in rhesus monkeys: effects of delta + mu and delta + kappa agonists on schedule-controlled responding and thermal nociception. J Pharmacol Exp Ther (2003) 1.21
Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys. Neuropsychopharmacology (2009) 1.18
Antinociceptive effects of nociceptin/orphanin FQ administered intrathecally in monkeys. J Pain (2009) 1.14
Characterization of the complex morphinan derivative BU72 as a high efficacy, long-lasting mu-opioid receptor agonist. Eur J Pharmacol (2004) 1.12
Effects of intrathecally administered nociceptin/orphanin FQ in monkeys: behavioral and mass spectrometric studies. J Pharmacol Exp Ther (2006) 1.07
Comparison of the relative efficacy and potency of mu-opioid agonists to activate Galpha(i/o) proteins containing a pertussis toxin-insensitive mutation. J Pharmacol Exp Ther (2006) 1.07
Buprenorphine antagonism of mu opioids in the rhesus monkey tail-withdrawal procedure. J Pharmacol Exp Ther (1995) 1.06
Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112. Pain (2009) 1.05
Dose-related opposite modulation by nociceptin/orphanin FQ of substance P nociception in the nociceptors and spinal cord. J Pharmacol Exp Ther (1999) 1.05
Nociceptin/orphanin FQ receptor activation attenuates antinociception induced by mixed nociceptin/orphanin FQ/mu-opioid receptor agonists. J Pharmacol Exp Ther (2009) 1.04
The anxiolytic-like effects of the novel, orally active nociceptin opioid receptor agonist 8-[bis(2-methylphenyl)methyl]-3-phenyl-8-azabicyclo[3.2.1]octan-3-ol (SCH 221510). J Pharmacol Exp Ther (2008) 1.01
Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice. Eur J Pain (2005) 0.98
Apparent pA2 analysis on the respiratory depressant effects of alfentanil, etonitazene, ethylketocyclazocine (EKC) and Mr2033 in rhesus monkeys. J Pharmacol Exp Ther (1993) 0.97
Effects of butorphanol on morphine-induced itch and analgesia in primates. Anesthesiology (2007) 0.94
Buprenorphine and methoclocinnamox: agonist and antagonist effects on respiratory function in rhesus monkeys. Eur J Pharmacol (2000) 0.94
Effects of atypical kappa-opioid receptor agonists on intrathecal morphine-induced itch and analgesia in primates. J Pharmacol Exp Ther (2008) 0.94
Identification of an additional supraspinal component to the analgesic mechanism of action of buprenorphine. Br J Pharmacol (2009) 0.92
Differential in vivo potencies of naltrexone and 6beta-naltrexol in the monkey. J Pharmacol Exp Ther (2005) 0.92
Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine. J Med Chem (2011) 0.91
Buprenorphine activates mu and opioid receptor like-1 receptors simultaneously, but the analgesic effect is mainly mediated by mu receptor activation in the rat formalin test. J Pharmacol Exp Ther (2006) 0.91
The effects of nociceptin/orphanin FQ receptor agonist Ro 64-6198 and diazepam on antinociception and remifentanil self-administration in rhesus monkeys. Psychopharmacology (Berl) (2010) 0.89
Interactions between an N-methyl-D-aspartate antagonist and low-efficacy opioid receptor agonists in assays of schedule-controlled responding and thermal nociception. J Pharmacol Exp Ther (2006) 0.89
The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications. Curr Top Med Chem (2011) 0.89
Most efficient cocaine hydrolase designed by virtual screening of transition states. J Am Chem Soc (2008) 2.33
Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity. Mol Pharmacol (2008) 1.60
Design, preparation, and characterization of high-activity mutants of human butyrylcholinesterase specific for detoxification of cocaine. Mol Pharmacol (2010) 1.48
Cocaine esterase prevents cocaine-induced toxicity and the ongoing intravenous self-administration of cocaine in rats. J Pharmacol Exp Ther (2009) 1.19
Structural analysis of thermostabilizing mutations of cocaine esterase. Protein Eng Des Sel (2010) 1.10
Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies. Eur J Pharmacol (2007) 1.09
Long-lasting effects of a PEGylated mutant cocaine esterase (CocE) on the reinforcing and discriminative stimulus effects of cocaine in rats. Neuropsychopharmacology (2011) 1.06
Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112. Pain (2009) 1.05
The role of central gastrin-releasing peptide and neuromedin B receptors in the modulation of scratching behavior in rats. J Pharmacol Exp Ther (2011) 1.00
Amelioration of the cardiovascular effects of cocaine in rhesus monkeys by a long-acting mutant form of cocaine esterase. Neuropsychopharmacology (2011) 0.98
The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability. ACS Chem Neurosci (2012) 0.94
Effects of butorphanol on morphine-induced itch and analgesia in primates. Anesthesiology (2007) 0.94
Human B1 and B2 bradykinin receptors and their agonists target caveolae-related lipid rafts to different degrees in HEK293 cells. Biochemistry (2002) 0.92
Effects of mu, kappa, and delta opioid receptor agonists on the function of hypothalamic-pituitary-adrenal axis in monkeys. Psychoneuroendocrinology (2008) 0.89
The effects of nociceptin/orphanin FQ receptor agonist Ro 64-6198 and diazepam on antinociception and remifentanil self-administration in rhesus monkeys. Psychopharmacology (Berl) (2010) 0.89
Subunit stabilization and polyethylene glycolation of cocaine esterase improves in vivo residence time. Mol Pharmacol (2011) 0.89
Physiological function of gastrin-releasing peptide and neuromedin B receptors in regulating itch scratching behavior in the spinal cord of mice. PLoS One (2013) 0.88
PEGylation of bacterial cocaine esterase for protection against protease digestion and immunogenicity. J Control Release (2009) 0.88
Differential effects of opioid-related ligands and NSAIDs in nonhuman primate models of acute and inflammatory pain. Psychopharmacology (Berl) (2013) 0.87
Effects of a long-acting mutant bacterial cocaine esterase on acute cocaine toxicity in rats. Drug Alcohol Depend (2011) 0.87
Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain. J Pharmacol Exp Ther (2013) 0.86
The spinal antinociceptive effects of endomorphins in rats: behavioral and G protein functional studies. Anesth Analg (2008) 0.84
DiPOA ([8-(3,3-diphenyl-propyl)-4-oxo-1-phenyl-1,3,8-triazaspiro[4.5]dec-3-yl]-acetic acid), a novel, systemically available, and peripherally restricted mu opioid agonist with antihyperalgesic activity: I. In vitro pharmacological characterization and pharmacokinetic properties. J Pharmacol Exp Ther (2004) 0.84
Electrospray sample deposition for matrix-assisted laser desorption/ionization (MALDI) and atmospheric pressure MALDI mass spectrometry with attomole detection limits. Rapid Commun Mass Spectrom (2004) 0.84
Repeated administration of a mutant cocaine esterase: effects on plasma cocaine levels, cocaine-induced cardiovascular activity, and immune responses in rhesus monkeys. J Pharmacol Exp Ther (2012) 0.83
Studies examining the relationship between the chemical structure of protoxin II and its activity on voltage gated sodium channels. J Med Chem (2014) 0.82
The fate of bacterial cocaine esterase (CocE): an in vivo study of CocE-mediated cocaine hydrolysis, CocE pharmacokinetics, and CocE elimination. J Pharmacol Exp Ther (2011) 0.82
Design and synthesis of 4-phenyl piperidine compounds targeting the mu receptor. Bioorg Med Chem Lett (2004) 0.81
Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists. Bioorg Med Chem Lett (2004) 0.81
Pharmacokinetic evidence for the long-lasting effect of nor-binaltorphimine, a potent kappa opioid receptor antagonist, in mice. Neurosci Lett (2013) 0.80
Solid-phase and solution-phase parallel synthesis of tetrahydro-isoquinolines via Pictet-Spengler reaction. Comb Chem High Throughput Screen (2002) 0.79
Novel, potent ORL-1 receptor agonist peptides containing alpha-Helix-promoting conformational constraints. J Med Chem (2002) 0.79
An efficient parallel synthesis of capsazepine and capsazepine analogs. Comb Chem High Throughput Screen (2004) 0.78
4-(2-pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists. Bioorg Med Chem Lett (2003) 0.77
Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294. Pulm Pharmacol Ther (2003) 0.77
Cysteine racemization during the Fmoc solid phase peptide synthesis of the Nav1.7-selective peptide--protoxin II. J Pept Sci (2012) 0.76
Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958. J Pharmacol Exp Ther (2007) 0.76
Dibenzazepines and dibenzoxazepines as sodium channel blockers. Bioorg Med Chem Lett (2014) 0.76
Parallel synthesis of a biased library of thiazolidinones as novel sodium channel antagonists. Comb Chem High Throughput Screen (2003) 0.75
Efficient medicinal chemistry. Comb Chem High Throughput Screen (2006) 0.75
1,3-Dihydro-2,1,3-benzothiadiazol-2,2-diones and 3,4-dihydro-1H-2,1,3-benzothidiazin-2,2-diones as ligands for the NOP receptor. Bioorg Med Chem Lett (2004) 0.75
Design and synthesis of novel small molecule N/OFQ receptor antagonists. Bioorg Med Chem Lett (2004) 0.75
8-Substituted analogues of 3-(3-cyclopentyloxy-4-methoxy-benzyl)-8-isopropyl-adenine: highly potent and selective PDE4 inhibitors. J Med Chem (2005) 0.75
Display of somatostatin-related peptides in the complementarity determining regions of an antibody light chain. Arch Biochem Biophys (2005) 0.75